Total trials
511
Active
46
Phase 3
71
Total enrollment
437,540
Pipeline matrix
Showing 40 of 83 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Faricimab | — | — | — | 3 | |||
| OCR SC | — | — | — | — | — | 1 | |
| LUCENTIS | — | — | — | — | — | 1 | |
| Risdiplam | — | — | — | — | 2 | ||
| Giredestrant | — | — | 6 | ||||
| Fulvestrant | — | — | — | 5 | |||
| LHRH Agonist | — | — | — | 3 | |||
| Everolimus | — | — | — | — | 2 | ||
| Exemestane | — | — | — | — | — | 1 | |
| Tamoxifen | — | — | — | — | — | 1 | |
| Dexamethasone Mouth Rinse | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | 24 | ||
| Tocilizumab | — | — | 11 | ||||
| Trastuzumab | — | — | 12 | ||||
| bevacizumab | — | — | — | 43 | |||
| Cobimetinib | — | — | — | — | 14 | ||
| Pertuzumab | — | — | 12 | ||||
| Docetaxel | — | — | — | 5 | |||
| Chemotherapy | — | — | — | — | 3 | ||
| paclitaxel | — | — | — | — | 28 | ||
| Divarasib | — | — | — | — | 5 | ||
| Vemurafenib | — | — | — | — | 5 | ||
| Vixarelimab | — | — | — | — | — | 4 | |
| Autogene cevumeran | — | — | — | — | 3 | ||
| Venetoclax | — | — | — | — | 3 | ||
| Entrectinib | — | — | — | — | — | 2 | |
| Trastuzumab Emtansine | — | — | — | — | — | 2 | |
| Pralsetinib | — | — | — | — | — | 2 | |
| RO7446603 | — | — | — | — | — | 1 | |
| Aflibercept | — | — | — | — | — | 1 | |
| GDC-4198 | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| cBTKi Monotherapy | — | — | — | — | — | 1 | |
| RO7837195 | — | — | — | — | — | 1 | |
| RO7837195 Matched Placebo | — | — | — | — | — | 1 | |
| Selnoflast | — | — | — | — | — | 1 | |
| Mosunetuzumab | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 | |
| GDC-1261 | — | — | — | — | — | 1 | |
| SBRT | — | — | — | — | — | 1 |
43 more active programs hidden
Next readouts
- 2025-07-16
- 2026-06-15
- 2026-06-30
- 2026-07-03
- 2026-07-09
- 2026-09-04
- 2026-10-31
- 2026-11-16
- 2026-11-18
- 2026-11-30
Top conditions
- Healthy Volunteer35
- Breast Cancer27
- Rheumatoid Arthritis21
- Colorectal Cancer18
- Solid Cancers18
- Non-Small Cell Lung Cancer18
- Asthma17
- Healthy Volunteers15
Frequently asked questions about Genentech, Inc.
- How many clinical trials does Genentech, Inc. have on ClinicalTrials.gov?
- Genentech, Inc. is listed as the lead sponsor on 511 clinical trials in ClinicalTrials.gov, 46 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Genentech, Inc.'s trials are in Phase 3?
- 71 of Genentech, Inc.'s trials are in Phase 3, spread across 83 active drug programs.
- What therapeutic areas does Genentech, Inc. focus on?
- Genentech, Inc.'s most-studied conditions on ClinicalTrials.gov are Healthy Volunteer, Breast Cancer, Rheumatoid Arthritis, Colorectal Cancer, Solid Cancers.
- When are Genentech, Inc.'s next clinical trial readouts?
- Genentech, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)”, expected around 2025-07-16.